A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Inclusion Criteria: * A diagnosis of high-grade glioma was established by pathological method,and the recurrency of the disease is ongoing. * The report of the pathological diagnosis contained the status of IDH gene, and showed that IDH1/2 mutation existed. * The age of the patient is between 18 years old and 70 years old. * The condition of the patient permits the procedure of chemotherapy using PCV schema. * The patient is informed consent, and willing to join in this research. Exclusion Criteria: * The diagnosis is not recurrent high-grade glioma. * The diagnosis of high-grade glioma was not established by pathological method. * No molecular neuropathological report is available, or the report showed that IDH1/2 mutation did not exist. * The age of the patient does not meet the requirement of this research. * The condition of the patient does not permit the procedure of chemotherapy using PCV schema. * There are other conditions that the clinicians believe that the PCV chemotherapy is not appropriate for the patient. * The patient is not willing to join in this research.